Join Professor Kirsten Gronbaek and Professor Uwe Platzbecker as they discuss the complexities behind the classification and prognostication of low-risk myelodysplastic syndromes (MDS). They dive into the historical context of MDS classification, the evolution of prognostic indexes such as IPSS and IPSSM, and the implications of recent molecular findings. This conversation highlights the challenges in defining "low-risk" MDS, the role of genetic mutations in prognosis, and the considerations for treatment strategies, including the potential for stem cell transplantation. Host: Professor Kirsten Gronbaek, University of Copenhagen, Denmark Guest: Professor Uwe Platzbecker, University Clinic of LeipzigLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us:
[email protected] to receive the EHA Educational Updates via https://eha.news/subscribe
Ireland